Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
Study Details
Study Description
Brief Summary
This phase II trial studies how well capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Drugs used in chemotherapy, such as capecitabine and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving capecitabine and cyclophosphamide daily may kill more tumor cells. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab together may be an effective treatment for breast cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
PRIMARY OBJECTIVES:
- To estimate the progression free survival (PFS).
SECONDARY OBJECTIVES:
-
To evaluate the overall response rate (ORR).
-
To evaluate the clinical benefit rate (CBR; complete response, partial response, and stable disease for >= 24 weeks).
-
To estimate the overall survival (OS).
-
To assess the safety and tolerability.
OUTLINE:
Patients receive capecitabine orally (PO) once daily (QD), cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab intravenously (IV) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment (chemotherapy, lapatinib ditosylate, trastuzumab) Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
Drug: capecitabine
Given PO
Other Names:
Drug: cyclophosphamide
Given PO
Other Names:
Drug: lapatinib ditosylate
Given PO
Other Names:
Biological: trastuzumab
Given IV
Other Names:
Other: laboratory biomarker analysis
Correlative studies
|
Outcome Measures
Primary Outcome Measures
- PFS [From the date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 1 year]
One-sided one-sample logrank test will be used to evaluate the improvement in PFS compared to the reported historical PFS rate.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed HER2-positive metastatic breast cancer
-
HER2 overexpression of tumor by either immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH); tumors tested by IHC must be 3+ positive; tumors tested by FISH must have a ratio of HER2:CEP17 > 2.0; when both tests are performed, the FISH result must be positive
-
Prior trastuzumab use in the adjuvant or metastatic setting
-
No more than two prior cytotoxic chemotherapeutic regimens for metastatic breast cancer. In addition, prior Trastuzumab emtansine (TDM-1, Kadcyla) is allowed.
-
Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
-
Absolute neutrophil count (ANC) >= 1500/mm^3
-
Platelets >= 100,000/mm^3
-
Hemoglobin >= 9 g/dL
-
Bilirubin =< 1.5 x upper limit of normal (ULN)
-
Serum creatinine =< 1.5 x ULN or calculated creatinine clearance >= 60 ml/min
-
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
-
Fully recovered from toxicity due to prior therapy
-
Capable of understanding the informed consent and complying with the protocol and signed the informed consent document prior to any study-specific screening procedures or evaluations being performed
-
Must be able to swallow pills
-
May have either measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
-
Sexually active participants must agree to use a medically accepted barrier method of contraception (i.e. male condom or female condom) during the course of the study and for 3 months following discontinuation of study treatments; for participants of childbearing potential, a barrier method and a second method of contraception must be used
-
Participants of childbearing potential must have a negative pregnancy test at screening and enrollment; participants of childbearing potential are defined as premenopausal females capable of becoming pregnant, i.e. females who have had any evidence of menses in the past 12 months with the exception of those who had prior hysterectomy (oophorectomy or surgical sterilization); however, women who have been amenorrheic for >= 12 months are still considered to be of childbearing potential if the amenorrhea is possibly due to any other cause including prior chemotherapy, antiestrogens, or ovarian suppression
Exclusion Criteria:
-
Prior treatment with capecitabine or lapatinib
-
Radiation therapy within 2 weeks before the first dose of study treatment
-
Hormonal therapy within 2 weeks before the first dose of study treatment
-
Cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks before the first dose of study treatment
-
Biologic therapy (including antibodies [other than trastuzumab], immune modulators, cytokines) within 4 weeks before the first dose of study treatment; Note: there is no washout period required for trastuzumab
-
Any other type of investigational agent within 4 weeks before the first dose of study treatment
-
Major surgery, or not recovered from major surgery within 4 weeks before the first dose of study treatment
-
Untreated, symptomatic, or progressive brain metastases; participants must have no radiographic or other signs of progression in the brain for >= 1 month after completion of local therapy; any corticosteroid use for brain metastases must have been discontinued without the subsequent appearance of symptoms for >= 4 weeks prior to first study treatment
-
Uncontrolled significant intercurrent illness that would preclude the patient from study participation per investigator assessment
-
Left ventricular ejection fraction (LVEF) =< 50% as documented by multi gated acquisition scan (MUGA) or echocardiogram performed within 28 days prior to the first study treatment
-
Currently receiving anticoagulation with therapeutic doses of warfarin (low-molecular weight heparin is permitted)
-
Pregnant or breastfeeding
-
Known to be positive for the human immunodeficiency virus (HIV) (a test for HIV at screening is not required)
-
Have acute or currently active/requiring anti-viral therapy hepatic or biliary disease (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
-
Previously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)
-
Any other diagnosis of malignancy or evidence of malignancy (except non-melanoma skin cancer, in-situ carcinoma of the cervix) within 2 years prior to screening for this study
-
Unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | USC Norris Comprehensive Cancer Center | Los Angeles | California | United States | 90033 |
Sponsors and Collaborators
- University of Southern California
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Darcy V Spicer, MD, University of Southern California
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1B-12-10
- NCI-2013-01086
- P30CA014089